References
- Gibson L. WHO puts abortifacients on its essential drug list [News Roundup]. BMJ. 2005; 331: 68.
- Fiala C, Winikoff B, Helstrfm L, et al. Acceptability of home-use of misoprostol in medical abortion. Contraception. 2004; 70: 387–92.
- Shah R, Baji S, Kalgutkar S. Attitudes about medical abortion among Indian women. International Journal of Gynecology and Obstetrics. 2005; 89: 69–70.
- Planned Parenthood Wisconsin develops communication tools that work. Mife Matters. 2005;11. : 10.
- Murthy AS, Creinin MD, Harwood B, et al. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception. 2005; 71: 333–36.
- Shannon C, Brothers LP, Philip NM, et al. Infection after medical abortion: a review of the literature. Contraception. 2004; 70: 183–90.
- Grimes DA. Risks of mifepristone abortion in context [Commentary]. Contraception. 2005; 71: 161.
- Cowett AA, Cohen LS, Lichtenberg ES, et al. Ultrasound evaluation of the endometrium after medical termination of pregnancy. Obstetrics and Gynecology. 2004; 103(5): 871–75.